Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the drug Cefotolan Pivoxil Tablets, which is indicated for various infections caused by sensitive bacteria [1]. Group 1 - The drug Cefotolan Pivoxil Tablets is suitable for treating infections such as folliculitis, infectious pustulosis, subcutaneous abscess, hidradenitis, pharyngitis, acute and chronic bronchitis, tonsillitis, otitis media, sinusitis, and periodontitis [1].

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the drug Cefotolan Pivoxil Tablets, which is indicated for various infections caused by sensitive bacteria [1]. Group 1 - The drug Cefotolan Pivoxil Tablets is suitable for treating infections such as folliculitis, infectious pustulosis, subcutaneous abscess, hidradenitis, pharyngitis, acute and chronic bronchitis, tonsillitis, otitis media, sinusitis, and periodontitis [1].

Core Viewpoint - The company has received a drug registration certificate for its product, Cefotolan Pivoxil Tablets, which is expected to enhance its product line and market competitiveness [1] Group 1: Product Registration - The company's wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has obtained a drug registration certificate from the National Medical Products Administration for Cefotolan Pivoxil Tablets, classified as a chemical drug category 4, with a specification of 0.1g [1] - This product is indicated for various infections caused by bacteria sensitive to this formulation [1] Group 2: Market Position - Currently, there are two companies, including Qingyutang, that have passed the consistency evaluation or are deemed to have passed it for this drug formulation [1] - Qingyutang is the first domestic generic manufacturer for this dosage form, apart from the original manufacturer [1] Group 3: Future Implications - The acquisition of the drug registration certificate is expected to enrich the subsidiary's product line and enhance its market competitiveness [1] - However, the production and sales situation of the product, as well as its specific impact on the company's performance, remain uncertain due to industry policies and market environment changes [1]